Rapid Molecular Testing Service for Public Health Wales

Essential supporting pneumonia and meningoencephalitis syndromic algorithm. * Offer must include all instruments, consumables, reagent, support, service and maintenance. * Consideration needs to be taken into capital money investment by Welsh Government in new equipment (BioFire Film Arrays; ePlex and Cepheid) to support rapid diagnosis in the pandemic as these still have an expected shelf life of another 5 years. * In addition, we have some reagent rental instruments in the Network. * Minimal processing time will be required for specimen investigation. * Speed of turnaround time for result will be essential. * Multiplex will be preferred over singleplex targets. * Software interpretation of result and interface to LIMS is essential. * High negative predictive, Sensitivity and Specificity is essential. * Reduce the need for specialist technical interpretation and handling. * Instruments and associated reagents must be complaint with UK Quality marking for equipment, reagents and consumables. * The service is to be fully functional by 1st July 2023. * The current estimates on numbers is a minimum of 20 rapid test per site in the network. * There are 12 Public Health Wales sites with potential to include 3 non-Public Health Wales sites. * Maintain and provide the ability to meet the increase demand and a robust supply chain. * Support our adherence to antibiotic sensitivity testing and reporting guidelines.

Desirable supporting bone and tissue; gastrointestinal and sexual transmitted syndromic algorithm. * Offer must include all instruments, consumables, reagent, support, service and maintenance. * Consideration needs to be taken into capital money investment by Welsh Government in new equipment (BioFire Film Arrays; ePlex and Cepheid) to support rapid diagnosis in the pandemic as these still have an expected shelf life of another 5 years. * In addition, we have some reagent rental instruments in the Network. * Minimal processing time will be required for specimen investigation. * Health and Safety during the processing must minimise any potential incident, hazard or risk. * Speed of turnaround time for result will be essential. * Multiplex will be preferred over singleplex targets. * Software interpretation of result and interface to LIMS is essential. * High negative predictive, Sensitivity and Specificity is essential. * Reduce the need for specialist technical interpretation and handling. * Instruments and associated reagents must be complaint with UK Quality marking for equipment, reagents and consumables. * The service is to be fully functional by 1st July 2023. * The current estimates on numbers is a minimum of 20 rapid test per site in the network. * There are 12 Public Health Wales sites with potential to include 3 non-Public Health Wales sites. * Maintain and provide the ability to meet the increase demand and a robust supply chain. * Support our adherence to antibiotic sensitivity testing and reporting guidelines. * A robust and resilient support post service implementation.